Login to Your Account

Topotarget Investors Nervous About Belinostat NDA Delay

By Cormac Sheridan
Staff Writer

Wednesday, August 14, 2013

Investors in Topotarget A/S got a dose of the jitters on news that its development partner, Spectrum Pharmaceuticals Inc., will delay its new drug application (NDA) filing of Topotarget's belinostat to the fourth quarter, pushing into next year the payment dates for two badly needed milestones.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription